1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015-2019

The new report “Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - 2019” by Spearhead Acuity Business Research & Consulting group reveals that the North America continued to lead global anti-bacterial drugs market with a share of 38.9% in 2014 that translated into revenues worth US$ 16,907.3 million.

The report analyzes the global anti-bacterial drugs market in six regions of North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa. The global anti-bacterial market is inclined towards North America and Europe. The majority can be attributed to large volume generic sales as well as a strongest innovative R&D activity in the sector with a large number of companies such as Cubist Pharmaceuticals, Cempra, Actelion, Achaogen and Melinta. Europe and Asia-Pacific followed with market shares of 24.7% and 18.7% respectively. Asia-Pacific is expected to overtake Europe with expirations of several drugs that will be absorbed by the strong generics market by the end of this decade. China remains the largest supplier of raw materials and active moiety to drug manufacturers over the world. With emerging countries such as India and China, the Asia-Pacific region is expected to remain a major threat to innovators and originator companies developing new drugs.

In light of the recent violent clashes throughout different regions of Europe and unpredicted future in conflict regions such as Ukraine and Syria have taken considerable toll in investments for healthcare and progress. There are several initiatives that continue to support the development such as the New Drugs for Bad Bugs (ND4BB) initiative and the IMI-funded COMBACTE project, which aims to give antibiotic drug development a much-needed boost by pioneering new ways of designing and implementing efficient clinical trials for novel antibiotics. These initiatives will drive the innovation of the drugs market in coming years. Price fixing also tends to restrict revenues in the region and other challenges include regulatory hurdles such that new drugs need to show non-inferiority in clinical trials within a margin of 10% as compared with current gold standards.

This report covers major anti-bacterial drug brands by 18 major companies such as Merck & Co, Pfizer Inc, Cubist Pharmaceuticals, Cempra Pharmaceuticals, Astrazeneca, Forest Pharmaceuticals, Actavis, Johnson & Johnson (Janssen Pharma), Mpex Pharmaceuticals Inc, GlaxoSmithKline plc, Takeda, Durata Pharmaceuticals, Targanta, Nektar, Paratek, The Medicines Company, Melinta and Optimer. This exhaustive report covers existing brands such as Cubicin (daptomycin), Teflaro/Zinforo (ceftaroline), Dificid (fidaxomicin), Dalvance (dalbavancin), Orbactiv (oritavancin), Sivextro (tedizolid), Zerbaxa (ceftolozane + tazobactam), Avycaz (ceftazidime-avibactam), Zyvox (linezolid), Avelox (moxifloxacin), Augmentin (amoxicillin + clavulanic acid), Zosyn/Tazocin (piperacillin + tazobactam), Invanz (ertapenem), Tygacil (tigecyline). The scope also covers analysis of stage three and stage two pipeline drugs such as Surotomycin, Solitaire (solithromycin), Delafloxacin, Plazomycin, Taksta (fusidic acid), Cadazolid, Carbavance, Eravacycline, Finafloxacin, Omadacycline, Zabofloxacin, Ramoplanin, Nemonoxacin and Relebactam (MK-7655).

Until recently, the anti-bacterial pipeline was considered to be completely dry with very few foreseen launches, however 2014-2015 saw five major launches with another 8 expected by the turn of the decade. The largest challenge for drug manufacturers was to overcome a barrage of highly drug-resistant superbugs that have been observed across hospitals across the world. Improper usage, dosage and treatment regimen followed by patients has now created significant damage in terms of health since drug-resistant bacteria are difficult to deal with using conventional pharmaceuticals. Consistent investment in research and development particularly by early-clinical stage companies has been successful in delivering a sustainable pipeline for the market. Several companies such as Cellceutix have expanded into the anti-bacterial market after discovery of effective lead compounds against highly difficult to treat pan-drug resistant microbes. Macrolides are expected to become the fastest growing segment within the anti-bacterial space in coming years.

Table Of Contents

Global Anti-Bacterial Drugs Market Assessment and Forecast: 2015-2019
Chapter 1 Preface
1.1 Research Scope
1.1.1 Market Segmentation
1.1.2 Postulations
1.2 Methodology of Research
1.2.1 Companies covered in this report
Chapter 2 Precis
2.1 Market Inferences
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Increasing incidence of hospital and community acquired bacterial infections pushing growth of brands and generics
3.1.2 Improving Legal Framework for provision of Incentives expected to drive growth
3.2 Market Inhibitors
3.2.1 Limited pipeline drugs and absence of new indication targets may lead to significant erosion against generics
3.3 Opportunities
3.3.1 RandD in treatment of carbapenem-resistant enterobacteria will open new market
3.3.2 Existence of Considerable Target Population in Emerging Economies
Chapter 4 Global Anti-Bacterial Drugs Market Assessment, by Current Marketed Brands - Size and Forecast, 2015 - 2019 (US$ Millions)
4.1 Introduction
4.2 Cubicin (daptomycin) Market, US$ Mn (2013 - 2019)
4.3 Teflaro/Zinforo (ceftaroline) Market, US$ Mn (2013 - 2019)
4.4 Dificid (fidaxomicin) Market, US$ Mn (2013 - 2019)
4.5 Dalvance (dalbavancin) Market, US$ Mn (2013 - 2019)
4.6 Orbactiv (oritavancin) Market, US$ Mn (2013 - 2019)
4.7 Sivextro (tedizolid) Market, US$ Mn (2013 - 2019)
4.8 Zerbaxa (ceftolozane + tazobactam) Market, US$ Mn (2013 - 2019)
4.9 Avycaz (ceftazidime-avibactam) Market, US$ Mn (2013 - 2019)
4.10 Zyvox (linezolid) Market, US$ Mn (2013 - 2019)
4.11 Avelox (moxifloxacin) Market, US$ Mn (2013 - 2019)
4.12 Augmentin (amoxicillin + clavulanic acid) Market, US$ Mn (2013 - 2019)
4.13 Zosyn/Tazocin (piperacillin + tazobactam) Market, US$ Mn (2013 - 2019)
4.14 Invanz (ertapenem) Market, US$ Mn (2013 - 2019)
4.15 Tygacil (tigecyline) Market, US$ Mn (2013 - 2019)
4.16 Other Prominent Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
Chapter 5 Global Anti-Bacterial Drugs Market Assessment for Pipeline Drugs - Size and Forecast, 2015 - 2019 (US$ Millions)
5.1 Introduction
5.2 Surotomycin Market, US$ Mn (2013 - 2019)
5.3 Solitaire (solithromycin) Market, US$ Mn (2013 - 2019)
5.4 Delafloxacin Market, US$ Mn (2013 - 2019)
5.5 Plazomycin Market, US$ Mn (2013 - 2019)
5.6 Taksta (fusidic acid) Market, US$ Mn (2013 - 2019)
5.7 Cadazolid Market, US$ Mn (2013 - 2019)
5.8 Carbavance Market, US$ Mn (2013 - 2019)
5.9 Eravacycline Market, US$ Mn (2013 - 2019)
5.10 Other Early-Stage Anti-Bacterial Candidates
5.10.1 Finafloxacin
5.10.2 Omadacycline
5.10.3 Zabofloxacin
5.10.4 Ramoplanin
5.10.5 Nemonoxacin
5.10.6 Relebactam (MK-7655)
Chapter 6 Global Anti-Bacterial Drugs Market Assessment -Size and Forecast, By Geography, 2015 - 2019 (US$ Millions)
6.1 Introduction
6.2 North America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.3 Europe Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.4 Asia-Pacific Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.5 Latin America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.6 Middle-East Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.7 Africa Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
Chapter 7 Key Players Analysis: Global Anti-Bacterial Drugs Market, 2014 (%)
7.1 Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%)
7.2 Global Anti-Bacterial Drugs Market: Recent Developments 2013-2015
7.2.1 Mergers and Acquisitions
7.2.2 New Product Launches and Approvals
7.3 Competitive Landscape: Strategies
Chapter 8 Epilogue


List of Figures

FIG. 1 Market Segmentation: Anti-Bacterial Drugs Market Assessment and Forecast (2015-2019)
FIG. 2 Research Methodology: Global Anti-Bacterial Drugs Market Assessment
FIG. 3 Global Anti-Bacterial Drugs Market Share, by Geography 2014 and 2019 (% Share - US$ Million)
FIG. 4 Global Anti-Bacterial Drugs Market - Cubicin (daptomycin) Revenues 2013 - 2019 (US$ Millions)
FIG. 5 Global Anti-Bacterial Drugs Market - Teflaro/Zinforo (ceftaroline) Revenues 2013 - 2019 (US$ Millions)
FIG. 6 Global Anti-Bacterial Drugs Market - Dificid (fidaxomicin) Revenues 2013 - 2019 (US$ Millions)
FIG. 7 Global Anti-Bacterial Drugs Market - Dalvance (dalbavancin) Revenues 2013 - 2019 (US$ Millions)
FIG. 8 Global Anti-Bacterial Drugs Market - Orbactiv (oritavancin) Revenues 2013 - 2019 (US$ Millions)
FIG. 9 Global Anti-Bacterial Drugs Market - Sivextro (tedizolid-phosphate) Revenues 2013 - 2019 (US$ Millions)
FIG. 10 Global Anti-Bacterial Drugs Market - Zerbaxa (ceftolozane + tazobactam) Revenues 2013 - 2019 (US$ Millions)
FIG. 11 Global Anti-Bacterial Drugs Market - Avycaz (ceftazidime-avibactam) Revenues 2013 - 2019 (US$ Millions)
FIG. 12 Global Anti-Bacterial Drugs Market - Zyvox (linezolid) Revenues 2013 - 2019 (US$ Millions)
FIG. 13 Global Anti-Bacterial Drugs Market - Avelox (moxifloxacin) Revenues 2013 - 2019 (US$ Millions)
FIG. 14 Global Anti-Bacterial Drugs Market - Augmentin (amoxicillin + clavulanic acid) Revenues 2013 - 2019 (US$ Millions)
FIG. 15 Global Anti-Bacterial Drugs Market - Zosyn/Tazocin (piperacillin + tazobactam) Revenues 2013 - 2019 (US$ Millions)
FIG. 16 Global Anti-Bacterial Drugs Market - Invanz (ertapenem) Revenues 2013 - 2019 (US$ Millions)
FIG. 17 Global Anti-Bacterial Drugs Market - Tygacil (tigecyline) Revenues 2013 - 2019 (US$ Millions)
FIG. 18 Global Anti-Bacterial Drugs Market - Other Anti-Bacterial Drug Revenues 2013 - 2019 (US$ Millions)
FIG. 19 Global Anti-Bacterial Drugs Market - Surotomycin Revenues 2013 - 2019 (US$ Millions)
FIG. 20 Global Anti-Bacterial Drugs Market - Solitaire (solithromycin) Revenues 2013 - 2019 (US$ Millions)
FIG. 21 Global Anti-Bacterial Drugs Market - Delafloxacin Revenues 2013 - 2019 (US$ Millions)
FIG. 22 Global Anti-Bacterial Drugs Market - Plazomycin Revenues 2013 - 2019 (US$ Millions)
FIG. 23 Global Anti-Bacterial Drugs Market - Taksta Revenues 2013 - 2019 (US$ Millions)
FIG. 24 Global Anti-Bacterial Drugs Market - Cadazolid Revenues 2013 - 2019 (US$ Millions)
FIG. 25 Global Anti-Bacterial Drugs Market - Carbavance Revenues 2013 - 2019 (US$ Millions)
FIG. 26 Global Anti-Bacterial Drugs Market - Eravacycline Revenues 2013 - 2019 (US$ Millions)
FIG. 27 North America Anti-Bacterial Drugs Market Revenues 2013 - 2019 (US$ Millions)
FIG. 28 Europe Anti-Bacterial Drugs Market Revenues 2013 - 2019 (US$ Millions)
FIG. 29 Asia-Pacific Anti-Bacterial Drugs Market Revenues 2013 - 2019 (US$ Millions)
FIG. 30 Latin-America Anti-Bacterial Drugs Market Revenues 2013 - 2019 (US$ Millions)
FIG. 31 Middle-East Anti-Bacterial Drugs Market Revenues 2013 - 2019 (US$ Millions)
FIG. 32 Africa Anti-Bacterial Drugs Market Revenues 2013 - 2019 (US$ Millions)
FIG. 33 Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%)


List of Tables

TABLE 1 List of companies covered in this report
TABLE 2 Global Anti-Bacterial Drugs Market, by Geography, 2013 - 2019 (US$ Mn) (CAGR: 2015 - 2019)



Companies Mentioned
Pfizer, Cubist (Merck), GlaxoSmithKline (GSK), Actavis Pharmaceuticals, Cempra Pharmaceuticals, The Medicines Company and Durata Therapeutics.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021, to reach USD 4.73 billion by 2021 from USD 3.77 billion in 2016. The growth of this market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Global Feed Antibiotics Market

December 2016 $ 4250

Acetic Acid Markets In China

January 2017 $ 4000

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the UK

  • February 2017
    2 pages
  • Anti-Infective  

  • United Kingdom  

View report >

Anti-Infective Market in the US and Canada

  • February 2017
    6 pages
  • Anti-Infective  

  • Canada  

    United States  

View report >

Anti-Infective Market in the US

  • February 2017
    9 pages
  • Anti-Infective  

    Cell Therapy  

  • United States  

View report >

Related Market Segments :

Anti-Infective
Pharmaceutical

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.